{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hemoglobinopathy%3B+With+Thalassemia&page=7",
    "query": {
      "condition": "Hemoglobinopathy; With Thalassemia",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 208,
    "total_pages": 21,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hemoglobinopathy%3B+With+Thalassemia&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hemoglobinopathy%3B+With+Thalassemia&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T02:57:53.631Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00408447",
      "title": "Stem Cell Transplant in Sickle Cell Disease and Thalassemia",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Beta Thalassemia"
      ],
      "interventions": [
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic stem cell transplant",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Month to 30 Years"
      },
      "enrollment_count": 53,
      "start_date": "2004-09",
      "completion_date": "2025-02",
      "has_results": false,
      "last_update_posted_date": "2024-06-13",
      "last_synced_at": "2026-10-14T02:57:53.631Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00408447"
    },
    {
      "nct_id": "NCT06647979",
      "title": "Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)",
        "Beta-Thalassemia",
        "Transfusion Dependent Beta-Thalassaemia"
      ],
      "interventions": [
        {
          "name": "autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sequencing Assay for Variant rs114518452",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "Daniel Bauer",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "13 Years to 40 Years"
      },
      "enrollment_count": 10,
      "start_date": "2025-12-01",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2026-02-03",
      "last_synced_at": "2026-10-14T02:57:53.631Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06647979"
    },
    {
      "nct_id": "NCT01962415",
      "title": "Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Immunodeficiency (PID)",
        "Congenital Bone Marrow Failure Syndromes",
        "Inherited Metabolic Disorders (IMD)",
        "Hereditary Anemias",
        "Inflammatory Conditions",
        "Systemic Juvenile Idiopathic Arthritis (sJIA)",
        "Juvenile Rheumatoid Arthritis (JRA)"
      ],
      "interventions": [
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Paul Szabolcs",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "2 Months to 55 Years"
      },
      "enrollment_count": 100,
      "start_date": "2014-02-04",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2025-12-15",
      "last_synced_at": "2026-10-14T02:57:53.631Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01962415"
    },
    {
      "nct_id": "NCT02675959",
      "title": "Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Defibrotide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York Medical College",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "6 Months to 21 Years"
      },
      "enrollment_count": 40,
      "start_date": "2017-07-01",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-27",
      "last_synced_at": "2026-10-14T02:57:53.631Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Gainesville, Florida • Valhalla, New York + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Valhalla",
          "state": "New York"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02675959"
    },
    {
      "nct_id": "NCT02326597",
      "title": "Decision Aid for Therapeutic Options In Sickle Cell Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Sickle Cell Anemia",
        "Hemoglobin SS",
        "Hemoglobin SC",
        "Hemoglobin Beta Thalassemia"
      ],
      "interventions": [
        {
          "name": "Decision Aid Tool",
          "type": "OTHER"
        },
        {
          "name": "Standard Practice",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "8 Years to 80 Years"
      },
      "enrollment_count": 134,
      "start_date": "2015-01",
      "completion_date": "2017-04-17",
      "has_results": true,
      "last_update_posted_date": "2018-10-09",
      "last_synced_at": "2026-10-14T02:57:53.631Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02326597"
    },
    {
      "nct_id": "NCT00034528",
      "title": "Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hemoglobinopathies",
        "Anemia, Sickle Cell",
        "Hemoglobin SC Disease",
        "Thalassemia",
        "Thalassemia Major"
      ],
      "interventions": [
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "FK506",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2001-09",
      "completion_date": "2003-11",
      "has_results": false,
      "last_update_posted_date": "2013-05-01",
      "last_synced_at": "2026-10-14T02:57:53.631Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00034528"
    },
    {
      "nct_id": "NCT00001958",
      "title": "Hydroxyurea to Treat Beta-Thalassemia (Cooley's Anemia)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Beta Thalassemia",
        "Hemoglobinopathy"
      ],
      "interventions": [
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 100,
      "start_date": "1999-12",
      "completion_date": "2002-02",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-10-14T02:57:53.631Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001958"
    },
    {
      "nct_id": "NCT00427661",
      "title": "A Pilot Study of HSCT for Patients With High-risk Hemoglobinopathy Using a Nonmyeloablative Preparative Regimen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Thalassemia",
        "Hemoglobinopathies"
      ],
      "interventions": [
        {
          "name": "Busulfan; Fludarabine; cyclosporine A and MMF",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "3 Years to 35 Years"
      },
      "enrollment_count": 8,
      "start_date": "2002-06",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2016-08-18",
      "last_synced_at": "2026-10-14T02:57:53.631Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00427661"
    },
    {
      "nct_id": "NCT04770779",
      "title": "A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Transfusion-dependent Alpha-Thalassemia",
        "Transfusion-dependent Beta-Thalassemia"
      ],
      "interventions": [
        {
          "name": "Placebo Matching Mitapivat",
          "type": "DRUG"
        },
        {
          "name": "Mitapivat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agios Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 258,
      "start_date": "2021-11-30",
      "completion_date": "2029-06",
      "has_results": true,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-10-14T02:57:53.631Z",
      "location_count": 10,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Oakland, California + 7 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04770779"
    },
    {
      "nct_id": "NCT01758042",
      "title": "Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Kidney Disease",
        "Acute Myeloid Leukemia (AML)",
        "Acute Lymphoblastic Leukemia (ALL)",
        "Chronic Myelogenous Leukemia (CML)",
        "Chronic Lymphocytic Leukemia (CLL)",
        "Non-Hodgkin's Lymphoma (NHL)",
        "Hodgkin Disease",
        "Multiple Myeloma",
        "Myelodysplastic Syndrome (MDS)",
        "Aplastic Anemia",
        "AL Amyloidosis",
        "Diamond Blackfan Anemia",
        "Myelofibrosis",
        "Myeloproliferative Disease",
        "Sickle Cell Anemia",
        "Autoimmune Diseases",
        "Thalassemia"
      ],
      "interventions": [
        {
          "name": "Haploidentical Bone Marrow/Kidney",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 10,
      "start_date": "2012-11",
      "completion_date": "2025-07",
      "has_results": false,
      "last_update_posted_date": "2026-03-06",
      "last_synced_at": "2026-10-14T02:57:53.631Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01758042"
    }
  ]
}